NOVARTIS INDIA LTD. - 500672 - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Pharma giant Novartis to evaluate India for more manufacturing capacity, top exec confirms
Novartis has invested over $300 million in the last 5 years in India. In India, portfolio of Novartis has both innovative and established medicines in the segments of cardiovascular, eye care, immunology, metabolic, neuroscience, oncology, respiratory and organ transplant
India needs regulatory data protection for drug research: Novartis CEO
India should have a regulatory data protection system in place to attract fundamental drug research from major pharmaceutical companies in the world, Novartis Chief Executive Officer Vasant Narasimhan said on Friday here. Speaking to reporters on the sidelines of the life sciences conclave 'BioAsia 2023' being held here, Narasimhan said great work has been done to streamline Intellectual Property (IP) issues which can be further improved. "I think the next step is when you think about how we generate data and how protected that is in regulatory filings. India does not have regulatory data protection," he said replying to a query. If one looks at any place in the world where there is significant fundamental drug research happening from multinational firms, there is regulatory data protection, including China, Narasimhan further said. The Novartis CEO added that getting approvals for clinical trials used to be very difficult in India earlier. However, with the new policy, the process NOVARTIS INDIA LTD. - 500672 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Biotech can become a powerhouse in India'
Novartis CEO Vasant Narasimhan on the impossible odds of drug discovery, R&D and India's regulatory regime NOVARTIS INDIA LTD. - 500672 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 NOVARTIS INDIA LTD. - 500672 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 NOVARTIS INDIA LTD. - 500672 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Intimation of Newspaper Advertisement regarding the Unaudited Financial Results of the Company for the third quarter and nine months ended December 31, 2022 NOVARTIS INDIA LTD. - 500672 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 NOVARTIS INDIA LTD. - 500672 - Board Meeting Outcome for Unaudited Financial Results Of The Company For The Third Quarter And Nine Months Ended December 31, 2022
Unaudited Financial Results of the Company for the third quarter and nine months ended December 31, 2022